This is the default that will apply unless there is sufficient justification for other levels of review. The HiREB uses proportionate review which determines if the research is greater than minimal risk (full Board review) or minimal risk (Delegated review).
Submissions are reviewed in the order of their arrival in the electronic eREB system. There are 2 submission deadlines per month, these being the second and last Tuesday of every month. Please see the www.hireb.ca website under Meetings & News for submission and meetings dates
All applications receive in-depth review by two Board members and the Chair. Greater than minimal risk studies are presented, discussed, and evaluated at a full Board meeting. Minimal risk studies do not require approval by the full Board; instead, the outcome of their review is ratified at the next full
The REB may vote to approve the application as submitted, to approve provisionally, with conditions, to defer a decision with recommendations for (usually major) changes, or to disapprove the application. Research may begin as soon as the local principal investigator receives a letter of authorization/final approval from the HiREB Chair indicating approval to proceed. Approval may be withdrawn (very rarely) by the Medical Advisory Committee, Board of Directors, or Joint Boards of Governors to whom all approvals are sent for review. A letter indicating the HiREB decision will be sent to the local principal investigator by the HiREB Chair, usually within one month of the submission deadline.
If the approval is conditional on modifications being made, research may not begin until these modifications have been verified and approved by the HiREB Chair and final approval has been provided.
All forms and correspondence submitted to the HiREB for review and/or approval from the REB must be signed by the Local Principal Investigator.